Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma

被引:20
|
作者
Caviglia, Gian Paolo [1 ]
Ciruolo, Michela [2 ]
Olivero, Antonella [1 ]
Carucci, Patrizia [2 ]
Rolle, Emanuela [2 ]
Rosso, Chiara [1 ]
Abate, Maria Lorena [1 ]
Risso, Alessandra [2 ]
Ribaldone, Davide Giuseppe [1 ,2 ]
Tandoi, Francesco [3 ]
Saracco, Giorgio Maria [1 ,2 ]
Bugianesi, Elisabetta [1 ,2 ]
Gaia, Silvia [2 ]
机构
[1] Univ Turin, Dept Med Sci, I-10100 Turin, Italy
[2] Citta Salute & Sci Univ Hosp, Div Gastroenterol, I-10100 Turin, Italy
[3] Citta Salute & Sci Univ Hosp, Dept Surg Sci, Gen Surg 2U, Liver Transplant Unit, I-10100 Turin, Italy
关键词
AFP; BCLC; biomarker; HCC; PIVKA-II; prognosis; POSITIVE TUMOR-MARKERS; LIVER FIBROSIS; PIVKA-II; AFP; MODEL;
D O I
10.3390/cancers12102776
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The prognosis of hepatocellular carcinoma is mainly driven by the stage of the tumor and by the overall liver function status. However, survival rates of patients with hepatocellular carcinoma are heterogeneous. In this study, we investigated whether circulating biomarkers might allow us to stratify the survival of patients with a new diagnosis of hepatocellular carcinoma. We observed that three biomarkers (namely AFP, PIVKA-II, and CYFRA 21-1) were independent predictors of overall survival. In addition, the combined use of these biomarkers allowed us to further stratify patients with hepatocellular carcinoma, according to their survival probability. This approach might help clinicians to tailor more personalized treatment strategies. Keratin 19 (K19) is a cancer stem cell marker expressed by a subpopulation of hepatocellular carcinoma (HCC), associated with tumor aggressiveness. We evaluated the prognostic value of serum K19 fragment (CYFRA 21-1), in comparison or in combination with alpha-fetoprotein (AFP) and protein induced by vitamin-K absence or antagonist-II (PIVKA-II), in patients with HCC. A total of 160 patients (28F/132M; median age 62, range 44-86 years) with a new diagnosis of HCC and available serum samples collected at tumor diagnosis were analyzed retrospectively. Median overall survival (OS) after HCC diagnosis was 35.1, 95% CI 27.1-70.5 months. Multivariate Cox regression analysis showed that CYFRA 21-1 > 2.7 ng/mL (hazard ratio (HR) = 3.39, p < 0.001), AFP > 20 ng/mL (HR = 2.27, p = 0.007), and PIVKA-II > 200 mAU/mL (HR = 2.17, p = 0.020) were independent predictors of OS. The combination of biomarkers positivity allowed us to stratify patients with HCC into four risk categories associated with a progressively lower survival probability (log-rank test, p < 0.001). CYFRA 21-1 resulted an independent prognostic factor of patients with HCC and its combination with AFP and PIVKA-II might be useful to tailor personalized treatment strategies.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [21] SERUM CYTOKERATIN-19 MEASURED BY CYFRA21-1 ASSAY IN PATIENTS WITH GASTROINTESTINAL AND GYNECOLOGIC MALIGNANCY
    SAKAHARA, H
    KOUSAKA, T
    KOBAYASHI, H
    YAO, ZS
    IMAMURA, M
    MORI, T
    KONISHI, J
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1994, 5 (05) : 1137 - 1140
  • [22] Clinical significance of preoperative assessment of carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (Cyfra 21-1) in NSCLC patients
    Szturmowicz, M.
    Rudzinski, R.
    Kacprzak, A.
    Langfort, R.
    Demkow, U.
    Bestry, I.
    Orlowski, T.
    LUNG CANCER, 2006, 52 : S29 - S29
  • [23] Increased Circulating Cytokeratin-19 (Cyfra 21-1) is Predictive of Poor Outcome of Locally Advanced Squamous Cell Carcinoma in Lung
    Wang, Jingbo
    Ji, Zhe
    Cao, Jianzhong
    Ma, Yan
    Jiang, Wei
    Liu, Lipin
    Men, Yu
    Xu, Cai
    Wang, Xiaozhen
    Hui, Zhou Guang
    Liang, Jun
    Lv, Jima
    Zhou, Zongmei
    Xiao, Zefen
    Feng, Qinfu
    Chen, Dongfu
    Zhang, Hongxing
    Yin, Weibo
    Wang, Luhua
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S847 - S848
  • [24] Prognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer
    Youtao Xu
    Lei Xu
    Mantang Qiu
    Jie Wang
    Qing Zhou
    Lin Xu
    Jian Wang
    Rong Yin
    Scientific Reports, 5
  • [25] Prognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer
    Xu, Youtao
    Xu, Lei
    Qiu, Mantang
    Wang, Jie
    Zhou, Qing
    Xu, Lin
    Wang, Jian
    Yin, Rong
    SCIENTIFIC REPORTS, 2015, 5
  • [26] PROGNOSTIC-SIGNIFICANCE OF SERUM FRAGMENTS OF CYTOKERATIN-19 MEASURED BY CYFRA-21-1 IN CERVICAL-CANCER
    BONFRER, JMG
    GAARENSTROOM, KN
    KENTER, GG
    KORSE, CM
    HART, AAM
    GALLEE, MPW
    HELMERHORST, TJM
    KENEMANS, P
    GYNECOLOGIC ONCOLOGY, 1994, 55 (03) : 371 - 375
  • [27] Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion
    Lai, RS
    Chen, CC
    Lee, PC
    Lu, JY
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1999, 29 (09) : 421 - 424
  • [28] Clinical significance of serum cytokeratin 19 fragment (CYFRA 21-1) in biliary tract cancers: a reliable biomarker for gallbladder carcinoma and intrahepatic cholangiocarcinoma
    Huang, Li
    Chen, Wei
    Liang, Peiwen
    Hu, Wenjie
    Zhang, Kunsong
    Chen, Bin
    Han, Yuyan
    Meng, Fanyin
    DeMorrow, Sharon
    Yin, Xiaoyu
    Lai, Jiaming
    Liang, Lijian
    HEPATOLOGY, 2014, 60 : 799A - 799A
  • [29] Role of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer
    Giovanella, L.
    Imperiali, M.
    Trimboli, P.
    SCIENTIFIC REPORTS, 2017, 7
  • [30] Role of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer
    L. Giovanella
    M. Imperiali
    P. Trimboli
    Scientific Reports, 7